Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Innate Pharma Appoints Markus Jensen As Chief Medical Officer

PRIVATEAug 10, 2026•about 1 hour ago

Position

Chief Medical Officer

Company

Innate Pharma SA

Markus Jensen
MarseilleBiotechnologyHealth CareTherapeutics

Description

Innate Pharma announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team. This appointment is effective September 1, 2026 and follows the company's strategic partnership with Sobi.

Company Information

Company

Innate Pharma SA

Location

Marseille, Provence Alpes Côte D'azur, France

About

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: monoclonal antibodies, multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC). Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, several ANKET® drug candidates to address multiple tumor types as well as IPH4502 a differentiated ADC in development in solid tumors.

Predictive Intelligence
Strategic

ML-powered predictions for Innate Pharma SA's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.